ASLAN Keeps Eye On Maximizing Values After Fundraising
This article was originally published in PharmAsia News
Executive Summary
ASLAN has closed a Series C round involving some new investors that puts the Singapore venture in a more comfortable financial position and may allow it to complete pivotal trials for its lead oncology project. But its CEO says the main focus will continue to be on maximizing asset values.
You may also be interested in...
VC Roundup: 2Q Financings Fall As Per-Company Averages Rise
Second quarter venture capital investment in biotech fell from the same period a year ago, but the total remains near record levels, since some early-stage companies have been able to raise big VC sums.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.